The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.
Age >= 18 years；
Eastern Cooperative Oncology Group (ECOG) score of 0-1;
Pancreatic cancer confirmed by histology or cytology;
Potentially resectable pancreatic cancer documented by contrast enhanced CT (or MRI) scan;
Have received systematic anti-tumor treatment.
Previous history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumor (TA and TIS) or other malignant tumors that have received radical treatment (at least 5 years before enrollment).
Active bacterial or fungal infection (> = level 2 of National Cancer Institute Common Toxicity Criteria (NCI-CTC), Version 3.0).
Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases considered by researchers to be out of the group.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborator
Fudan University
Collaborator
Shanghai Changzheng Hospital
Collaborator
The First Affiliated Hospital of Soochow University
Collaborator
Xuzhou Central Hospital
Collaborator